patient,additional_studies,tumor_tissue_site,histological_type,other_dx,gender,vital_status,days_to_birth,days_to_last_known_alive,days_to_death,days_to_last_followup,race_list,race,bcr_patient_barcode,tissue_source_site,patient_id,bcr_patient_uuid,history_of_neoadjuvant_treatment,informed_consent_verified,icd_o_3_site,icd_o_3_histology,icd_10,tissue_prospective_collection_indicator,tissue_retrospective_collection_indicator,days_to_initial_pathologic_diagnosis,age_at_initial_pathologic_diagnosis,year_of_initial_pathologic_diagnosis,ethnicity,person_neoplasm_cancer_status,performance_status_scale_timing,day_of_form_completion,month_of_form_completion,year_of_form_completion,stage_event,system_version,clinical_stage,pathologic_stage,tnm_categories,clinical_categories,clinical_T,clinical_N,clinical_M,pathologic_categories,pathologic_T,pathologic_N,pathologic_M,psa,psa_value,days_to_psa,gleason_grading,gleason_score,primary_pattern,secondary_pattern,tertiary_pattern,ann_arbor,b_symptoms,extranodal_involvement,serum_markers,igcccg_stage,masaoka_stage,karnofsky_performance_score,eastern_cancer_oncology_group,tobacco_smoking_history,year_of_tobacco_smoking_onset,stopped_smoking_year,number_pack_years_smoked,anatomic_neoplasm_subdivision,anatomic_neoplasm_subdivision_other,diagnosis,location_in_lung_parenchyma,residual_tumor,kras_mutation_found,kras_gene_analysis_performed,kras_mutation_result,egfr_mutation_performed,egfr_mutation_result,eml4_alk_translocation_performed,eml4_alk_translocation_result,eml4_alk_translocation_method,pulmonary_function_test_performed,pre_bronchodilator_fev1_percent,post_bronchodilator_fev1_percent,pre_bronchodilator_fev1_fvc_percent,post_bronchodilator_fev1_fvc_percent,dlco_predictive_percent,targeted_molecular_therapy,radiation_therapy,primary_therapy_outcome_success,new_tumor_events,new_tumor_event_after_initial_treatment,new_tumor_event,days_to_new_tumor_event_after_initial_treatment,new_neoplasm_event_types,new_neoplasm_event_type,progression_determined_by_list,progression_determined_by,locoregional_procedure,additional_surgery_locoregional_procedure,days_to_additional_surgery_locoregional_procedure,metastatic_procedure,additional_surgery_metastatic_procedure,days_to_additional_surgery_metastatic_procedure,additional_radiation_therapy,additional_pharmaceutical_therapy,drugs,drug,tx_on_clinical_trial,regimen_number,bcr_drug_barcode,bcr_drug_uuid,total_dose,total_dose_units,prescribed_dose,prescribed_dose_units,number_cycles,days_to_drug_therapy_start,days_to_drug_therapy_end,therapy_types,therapy_type,therapy_type_notes,drug_name,clinical_trail_drug_classification,regimen_indication,regimen_indication_notes,route_of_administrations,route_of_administration,therapy_ongoing,measure_of_response,radiations,radiation,bcr_radiation_barcode,bcr_radiation_uuid,days_to_radiation_therapy_start,days_to_radiation_therapy_end,radiation_type,radiation_type_notes,radiation_dosage,units,numfractions,anatomic_treatment_site,radiation_treatment_ongoing,course_number,follow_ups,follow_up,bcr_followup_barcode,bcr_followup_uuid,lost_follow_up,followup_case_report_form_submission_reason,followup_treatment_success,tumor_tissue_site_other,primary_lymph_node_presentation_assessment,lymph_node_examined_count,er_detection_method_text,pgr_detection_method_text,anatomic_neoplasm_subdivisions,her2_neu_chromosone_17_signal_ratio_value,axillary_lymph_node_stage_method_type,axillary_lymph_node_stage_other_method_descriptive_text,breast_carcinoma_surgical_procedure_name,breast_neoplasm_other_surgical_procedure_descriptive_text,breast_carcinoma_primary_surgical_procedure_name,surgical_procedure_purpose_other_text,histological_type_other,menopause_status,breast_carcinoma_progesterone_receptor_status,cytokeratin_immunohistochemistry_staining_method_micrometastasis_indicator,breast_carcinoma_immunohistochemistry_er_pos_finding_scale,immunohistochemistry_positive_cell_score,her2_immunohistochemistry_level_result,breast_cancer_surgery_margin_status,margin_status,initial_pathologic_diagnosis_method,init_pathology_dx_method_other,lab_procedure_her2_neu_in_situ_hybrid_outcome_type,breast_carcinoma_estrogen_receptor_status,lab_proc_her2_neu_immunohistochemistry_receptor_status,number_of_lymphnodes_positive_by_ihc,number_of_lymphnodes_positive_by_he,pos_finding_progesterone_receptor_other_measurement_scale_text,positive_finding_estrogen_receptor_other_measurement_scale_text,her2_erbb_pos_finding_cell_percent_category,pos_finding_her2_erbb2_other_measurement_scale_text,her2_erbb_method_calculation_method_text,her2_neu_and_centromere_17_copy_number_analysis_input_total_number_count,her2_and_centromere_17_positive_finding_other_measurement_scale_text,her2_erbb_pos_finding_fluorescence_in_situ_hybridization_calculation_method_text,fluorescence_in_situ_hybridization_diagnostic_procedure_chromosome_17_signal_result_range,first_nonlymph_node_metastasis_anatomic_sites,metastatic_site_at_diagnosis,metastatic_site_at_diagnosis_other,er_level_cell_percentage_category,progesterone_receptor_level_cell_percent_category,distant_metastasis_present_ind2,metastatic_breast_carcinoma_estrogen_receptor_status,metastatic_breast_carcinoma_estrogen_receptor_level_cell_percent_category,metastatic_breast_carcinoma_immunohistochemistry_er_pos_cell_score,pos_finding_metastatic_breast_carcinoma_estrogen_receptor_other_measuremenet_scale_text,metastatic_breast_carcinoma_estrogen_receptor_detection_method_text,metastatic_breast_carcinoma_progesterone_receptor_status,metastatic_breast_carcinoma_lab_proc_her2_neu_immunohistochemistry_receptor_status,metastatic_breast_carcinoma_progesterone_receptor_level_cell_percent_category,metastatic_breast_carcinoma_immunohistochemistry_pr_pos_cell_score,metastatic_breast_carcinoma_pos_finding_progesterone_receptor_other_measure_scale_text,metastatic_breast_carcinoma_progesterone_receptor_detection_method_text,metastatic_breast_carcinoma_her2_erbb_pos_finding_cell_percent_category,metastatic_breast_carcinoma_erbb2_immunohistochemistry_level_result,metastatic_breast_carcinoma_pos_finding_her2_erbb2_other_measure_scale_text,metastatic_breast_carcinoma_her2_erbb_method_calculation_method_text,metastatic_breast_carcinoma_lab_proc_her2_neu_in_situ_hybridization_outcome_type,metastatic_breast_carcinoma_fluorescence_in_situ_hybridization_diagnostic_proc_centromere_17_signal_result_range,her2_neu_and_centromere_17_copy_number_metastatic_breast_carcinoma_analysis_input_total_number_count,metastatic_breast_carcinoma_her2_neu_chromosone_17_signal_ratio_value,metastatic_breast_carcinoma_pos_finding_other_scale_measurement_text,metastatic_breast_carcinoma_her2_erbb_pos_finding_fluorescence_in_situ_hybridization_calculation_method_text,her2_neu_metastatic_breast_carcinoma_copy_analysis_input_total_number,her2_neu_breast_carcinoma_copy_analysis_input_total_number,breast_carcinoma_immunohistochemistry_progesterone_receptor_pos_finding_scale,breast_carcinoma_immunohistochemistry_pos_cell_score,postoperative_rx_tx,new_neoplasm_event_occurrence_anatomic_site,new_neoplasm_occurrence_anatomic_site_text,new_tumor_event_additional_surgery_procedure,days_to_new_tumor_event_additional_surgery_procedure,metastatic_breast_carcinoma_immunohistochemistry_er_positive_finding_scale_type,metastatic_breast_carcinoma_immunohistochemistry_progesterone_receptor_positive_finding_scale_type,height,weight,surgical_approach,peritoneal_wash,pct_tumor_invasion,neoplasm_histologic_grade,total_pelv_lnr,pln_pos_light_micro,pln_pos_ihc,total_pelv_lnp,total_aor_lnr,aln_pos_light_micro,aln_pos_ihc,total_aor-lnp,colorectal_cancer,diabetes,horm_ther,hypertension,birth_control_pill_history_usage_category,pregnancies,prior_tamoxifen_administered_usage_category,additional_treatment_completion_success_outcome,recurrence_second_surgery_neoplasm_surgical_procedure_name,recurrence_second_surgery_neoplasm_surgical_procedure_name_other,residual_disease_post_new_tumor_event_margin_status,laterality,lactate_dehydrogenase_result,serum_calcium_result,hemoglobin_result,platelet_qualitative_result,white_cell_count_result,erythrocyte_sedimentation_rate_result,number_of_lymphnodes_positive,patient_personal_medical_history_thyroid_gland_disorder_names,patient_personal_medical_history_thyroid_gland_disorder_name,patient_personal_medical_history_thyroid_other_specify_text,first_degree_relative_history_thyroid_gland_carcinoma_diagnosis_relationship_types,first_degree_relative_history_thyroid_gland_carcinoma_diagnosis_relationship_type,person_lifetime_risk_radiation_exposure_indicator,primary_thyroid_gland_neoplasm_location_anatomic_site,primary_neoplasm_focus_type,neoplasm_dimension,neoplasm_length,neoplasm_width,neoplasm_depth,lymph_node_preoperative_scan_indicator,lymph_node_preoperative_assessment_diagnostic_imaging_types,lymph_node_preoperative_assessment_diagnostic_imaging_type,extrathyroid_carcinoma_present_extension_status,metastatic_neoplasm_confirmed_diagnosis_method_names,metastatic_neoplasm_confirmed_diagnosis_method_name,metastatic_neoplasm_confirmed_diagnosis_method_text,metastatic_site,other_metastatic_site,genotype_analysis_performed_indicator,genotyping_results_gene_mutation_not_reported_reasons,genotyping_results_gene_mutation_not_reported_reason,braf_gene_genotyping_outcome_lab_results_text,ras_family_gene_genotyping_outcome_lab_results_text,ret_ptc_rearrangement_genotyping_outcome_lab_results_text,other_genotyping_outcome_lab_results_text,i_131_total_administered_preparation_technique,i_131_first_administered_dose,i_131_subsequent_administered_dose,i_131_total_administered_dose,radiation_therapy_administered_preparation_technique_text,radiation_therapy_administered_dose_text,radiosensitizing_agent_administered_indicator,post_surgical_procedure_assessment_thyroid_gland_carcinoma_status,new_tumor,new_neoplasm_confirmed_diagnosis_method_name,histologic_disease_progression_present_indicator,histologic_disease_progression_present_type,histologic_disease_progression_present_text,thyroid_gland_carcinoma_involvement_regional_lymph_node_type,thyroid_gland_carcinoma_regional_lymph_node_involvement_anatomic_sites_text,therapeutic_procedure_new_neoplasm_required_additional_therapy_type,preoperative_pretreatment_cea_level,non_nodal_tumor_deposits,circumferential_resection_margin,venous_invasion,lymphatic_invasion,perineural_invasion_present,microsatellite_instability,number_of_loci_tested,number_of_abnormal_loci,kras_mutation_codon,braf_gene_analysis_performed,braf_gene_analysis_result,synchronous_colon_cancer_present,history_of_colon_polyps,colon_polyps_present,loss_expression_of_mismatch_repair_proteins_by_ihc,loss_expression_of_mismatch_repair_proteins_by_ihc_results,loss_expression_of_mismatch_repair_proteins_by_ihc_result,number_of_first_degree_relatives_with_cancer_diagnosis,tumor_residual_disease,jewish_origin,progression_determined_by_notes,prior_glioma,history_ionizing_rt_to_head,tumor_location,supratentorial_localization,seizure_history,headache_history,mental_status_changes,visual_changes,sensory_changes,motor_movement_changes,first_presenting_symptom,first_presenting_symptom_longest_duration,asthma_history,eczema_history,hay_fever_history,mold_or_dust_allergy_history,first_diagnosis_age_asth_ecz_hay_fev_mold_dust,food_allergy_history,food_allergy_types,first_diagnosis_age_of_food_allergy,animal_insect_allergy_history,animal_insect_allergy_types,first_diagnosis_age_of_animal_insect_allergy,preoperative_corticosteroids,preoperative_antiseizure_meds,family_history_of_cancer,family_history_of_primary_brain_tumor,ldh1_mutation_tested,ldh1_mutation_test_method,ldh1_mutation_found,inherited_genetic_syndrome_found,inherited_genetic_syndrome_result,days_to_performance_status_assessment,patient_death_reason,primary_neoplasm_melanoma_dx,sites_of_primary_melanomas,primary_tumor_multiple_present_ind,primary_melanoma_at_diagnosis_count,site,primary_anatomic_site_count,breslow_depth_value,melanoma_clark_level_value,melanoma_ulceration_indicator,malignant_neoplasm_mitotic_count_rate,days_to_submitted_specimen_dx,distant_metastasis_anatomic_site,melanoma_origin_skin_anatomic_site,prior_systemic_therapy_types,prior_systemic_therapy_type,interferon_90_day_prior_excision_admin_indicator,new_tumor_dx_prior_submitted_specimen_dx,new_tumor_metastasis_anatomic_site,new_tumor_metastasis_anatomic_site_other_text,new_primary_melanoma_anatomic_site,new_primary_melanoma_anatomic_site_other_text,new_non_melanoma_event_histologic_type_text,subsequent_primary_melanoma_during_followup,country_of_procurement,city_of_procurement,reflux_history,antireflux_treatment,antireflux_treatment_types,antireflux_treatment_type,barretts_esophagus,h_pylori_infection,family_history_of_stomach_cancer,number_of_relatives_with_stomach_cancer,tumor_type,egfr_mutation_identified,eml4_alk_translocation_identified,lymphnode_neck_dissection,lymphnode_dissection_method_left,lymphnode_dissection_method_right,p53_gene_analysis,egfr_amplication_status,presence_of_pathological_nodal_extracapsular_spread,lymphovascular_invasion_present,hpv_status_by_p16_testing,hpv_status_by_ish_testing,alcohol_history_documented,frequency_of_alcohol_consumption,amount_of_alcohol_consumption_per_day,smokeless_tobacco_use_at_diag,smokeless_tobacco_use_regularly,smokeless_tobacco_use_per_day,smokeless_tobacco_use_age_at_start,smokeless_tobacco_use_age_at_quit,days_to_completion_of_curative_tx,method_of_curative_tx,disease_after_curative_tx,mitotane_therapy,mitotane_therapy_adjuvant_setting,therapeutic_mitotane_levels_achieved,therapeutic_mitotane_lvl_recurrence,mitotane_therapy_for_macroscopic_residual_disease,therapeutic_mitotane_lvl_macroscopic_residual,therapeutic_mitotane_lvl_progression,primary_pathology,ct_scan,ct_scan_findings,weiss_assessment_report,weiss_score,weiss_assessment_categories,nuclear_grade_III_IV,mitotic_rate,atypical_mitotic_figures,cytoplasm_presence_less_than_equal_25_percent,diffuse_architecture,necrosis,weiss_venous_invasion,sinusoid_invasion,invasion_of_tumor_capsule,mitoses_count,metastatic_neoplasm_initial_diagnosis_anatomic_sites,metastatic_neoplasm_initial_diagnosis_anatomic_site,excess_adrenal_hormone_history_types,excess_adrenal_hormone_history_type,excess_adrenal_hormone_diagnosis_method_type,germline_genotype_testing_report,germline_testing_performed,germline_genotype_test_categories,ret,vhl,nf1,nf1_clinical_diagnosis,sdha,sdhb,sdhc,sdhd,sdhaf2_sdh5,tmem127,max,zone_of_origin,tumor_levels,tumor_level,days_to_bone_scan_performed,bone_scan_results,diagnostic_ct_abd_pelvis_performed,days_to_diagnostic_computed_tomography_performed,diagnostic_ct_abd_pelvis_results,diagnostic_ct_abd_pelvis_result,diagnostic_mri_performed,days_to_diagnostic_mri_performed,diagnostic_mri_results,diagnostic_mri_result,lymphnodes_examined,number_of_lymphnodes_examined,source_of_patient_death_reason,biochemical_recurrence,days_to_first_biochemical_recurrence,history_of_disease,hiv_status,days_to_hiv_diagnosis,nadir_cd4_counts,cd4_counts_at_diagnosis,hiv_rna_load_at_diagnosis,prior_aids_conditions,hbv_test,hcv_test,hpv_test,kshv_hhv8_test,on_haart_therapy_prior_to_cancer_diagnosis,on_haart_therapy_at_cancer_diagnosis,cdc_hiv_risk_group,history_of_other_malignancy,history_immunological_diseases,history_immunological_disease,history_immunological_disease_other,history_immunosuppresive_rx_types,history_immunosuppresive_rx,history_immunosuppressive_rx_other,history_relevant_infectious_dx,history_relevant_infectious_dx_other,follicular_percent,lymph_node_involvement_sites,lymph_node_involvement_site,tumor_tissue_sites,extranodal_involvment_site_other,extranodal_sites_involvement_number,maximum_tumor_dimension,maximum_tumor_bulk_anatomic_site,days_to_sample_procurement,pos_lymph_node_locations,pos_lymph_node_location,pos_lymph_node_location_other,bone_marrow_biopsy_done,bone_marrow_involvement,bone_marrow_sample_histology,tests_performed,ldh_level,ldh_norm_range_upper,genetic_testing_results,genetic_testing_result,immunophenotypic_analysis_tested,immunophenotypic_analysis_method,immunophenotypic_analysis_results,mib1_positive_percentage_range,b_lymphocyte_genotyping_method,igh_genotype_results,igk_genotype_results,genetic_abnormalities,genetic_abnormality_testing_result,genetic_abnormality_tested,genetic_abnormality_tested_other,genetic_abnormality_method,genetic_abnormality_method_other,genetic_abnormality_results,genetic_abnormality_results_other,ebv_status_malignant_cells_method,epstein_barr_viral_status,ebv_positive_malignant_cells_percent,pet_scan_results,first_recurrence_biopsy_confirmed,first_progression_histology_type,first_progression_histology_type_other,stem_cell_transplantation,stem_cell_transplantation_type,days_to_stem_cell_transplantation,pharm_regimen,pharm_regimen_other,history_of_undescended_testis,level_of_non_descent,undescended_testis_corrected,undescended_testis_corrected_age,undescended_testis_method_left,undescended_testis_method_right,history_hypospadias,history_fertility,family_history_testicular_cancer,relation_testicular_cancer_list,relation_testicular_cancer,family_history_other_cancer,blood_relative_cancer_history_list,blood_relative_cancer_history,family_member_relationship_type,relative_family_cancer_hx_text,postoperative_tx_list,postoperative_tx,bilateral_diagnosis_timing_type,days_to_bilateral_tumor_dx,synchronous_tumor_histology_list,synchronous_tumor_histology,synchronous_tumor_histology_type,synchronous_tumor_histology_pct,testis_tumor_macroextent,testis_tumor_macroextent_other,testis_tumor_microextent,histology_list,histology,histological_percentage,intratubular_germ_cell_neoplasm,pre_orchi_serum_marker_info,days_to_pre_orchi_serum_test,pre_orchi_ldh,pre_orchi_hcg,pre_orchi_afp,pre_orchi_lh,pre_orchi_testosterone,post_orchi_serum_marker_info,days_to_post_orchi_serum_test,post_orchi_ldh,post_orchi_hcg,post_orchi_afp,post_orchi_lh,post_orchi_testosterone,post_orchi_lymph_node_dissection,molecular_test_result_list,molecular_test_result,first_treatment_success,days_to_second_biochemical_recurrence,days_to_third_biochemical_recurrence,tumor_progression_post_ht,type_ofprogression_of_disease_ht,history_pheo_or_para_include_benign,history_pheo_or_para_anatomic_site,outside_adrenal,disease_detected_on_screening,country_of_birth,state_province_of_procurement,age_began_smoking_in_years,initial_diagnosis_by,goblet_cells_present,history_of_esophageal_cancer,number_of_relatives_diagnosed,esophageal_tumor_cental_location,esophageal_tumor_involvement_sites,esophageal_tumor_involvement_site,columnar_metaplasia_present,columnar_mucosa_goblet_cell_present,columnar_mucosa_dysplasia,lymph_node_metastasis_radiographic_evidence,planned_surgery_status,treatment_prior_to_surgery,leiomyosarcoma_histologic_subtype,primary_tumor_lower_uterus_segment,leiomyosarcoma_major_vessel_involvement,synovial_sarcoma,ss18_ssx_fusion_status,ss18_ssx_testing_method,mpnst_neurofibromatosis,mpnst_neurofibromatosis_heredity,mpnst_exisiting_plexiform_neurofibroma,mpnst_nf1_genetic_testing,mpnst_specific_mutations,tumor_depth,tumor_total_necrosis_percent,tumor_necrosis_percent,mitotic_count,tumor_multifocal,discontiguous_lesion_count,tumor_sizes,tumor_size,radiologic_tumor_length,radiologic_tumor_width,radiologic_tumor_depth,pathologic_tumor_length,pathologic_tumor_width,pathologic_tumor_depth,radiologic_tumor_burden,pathologic_tumor_burden,local_disease_recurrence,metastatic_diagnosis,contiguous_organ_resection_site,other_contiguous_organ_resection_site,contiguous_organ_invaded,well_differentiated_liposarcoma_primary_dx,days_to_well_differentiated_liposarcoma_primary_dx,days_to_well_differentiated_liposarcoma_resection,new_tumor_cellular_differentiation,number_of_successful_pregnancies_which_resulted_in_at_least_1_live_birth,patient_pregnancy_spontaneous_abortion_count,patient_pregnancy_therapeutic_abortion_count,ectopic_pregnancy_count,pregnancy_stillbirth_count,female_breast_feeding_or_pregnancy_status_indicator,total_number_of_pregnancies,patient_history_immune_system_and_related_disorders_names,patient_history_immune_system_and_related_disorders_name,patient_history_immune_system_and_related_disorders_text,assessment_timepoint_category,tumor_response_cdus_type,keratinizing_squamous_cell_carcinoma_present_indicator,lymph_node_location_positive_pathology_names,lymph_node_location_positive_pathology_name,lymph_node_location_positive_pathology_text,hysterectomy_performed_type,hysterectomy_performed_text,cervical_neoplasm_pathologic_margin_involved_type,cervical_neoplasm_pathologic_margin_involved_text,cervical_carcinoma_pelvic_extension_text,lymphovascular_invasion_indicator,cervical_carcinoma_corpus_uteri_involvement_indicator,days_to_fdg_or_ct_pet_performed,standardized_uptake_value_cervix_uteri_assessment_measurement,fdg_or_ct_pet_performed_outcomes,diagnostic_mri_result_outcomes,diagnostic_ct_result_outcomes,diagnostic_ct_result_outcome,human_papillomavirus_types,human_papillomavirus_type,human_papillomavirus_other_type_text,human_papillomavirus_laboratory_procedure_performed_name,human_papillomavirus_laboratory_procedure_performed_text,oligonucleotide_primer_pair_laboratory_procedure_performed_name,oligonucleotide_primer_pair_laboratory_procedure_performed_text,laboratory_procedure_tumor_marker_squamous_cell_carcinoma_antigen_result_value,days_to_laboratory_procedure_tumor_marker_squamous_cell_carcinoma_antigen_result,death_cause_text,pregnant_at_diagnosis,treatment,radiation_therapy_info,radiation_therapy_not_administered_reason,radiation_therapy_not_administered_specify,brachytherapy_method_type,brachytherapy_method_other_specify_text,brachytherapy_first_reference_point_administered_total_dose,rt_administered_type,rt_pelvis_administered_total_dose,external_beam_radiation_therapy_administered_paraaortic_region_lymph_node_dose,concurrent_rx_tx_info,chemotherapy_negation_radiation_therapy_concurrent_not_administered_reason,chemotherapy_negation_radiation_therapy_concurrent_administered_text,concurrent_rx_tx,chemotherapy_regimen_type,other_chemotherapy_agent_administration_specify,concurrent_chemotherapy_dose,dose_frequency_text,agent_total_dose_count,new_neoplasm_event_post_initial_therapy_diagnosis_method_type,new_neoplasm_event_post_initial_therapy_diagnosis_method_text,eye_color,tumor_tissue_site_list,tumor_morphology_list,tumor_morphology,tumor_morphology_percentage,cytogenetic_abnormality_list,cytogenetic_abnormality,gene_expression_profile_list,gene_expression_profile,pet_ct_standardized_values,extravascular_matrix_patterns,microvascular_density_mvd,tumor_infiltrating_lymphocytes,tumor_infiltrating_macrophages,tumor_basal_diameter,tumor_basal_diameter_mx,tumor_thickness,tumor_thickness_measurement,extrascleral_extension,extranocular_nodule_size,tumor_shape_pathologic_clinical,metastatic_site_list,new_neoplasm_histology_other,site_of_additional_surgery_new_tumor_event_mets,relative_family_cancer_history,cancer_first_degree_relative,family_cancer_type_txt,history_hepato_carcinoma_risk_factors,hist_hepato_carc_fact,hist_hepato_carcinoma_risk,post_op_ablation_embolization_tx,specimen_collection_method_name,history_prior_surgery_type_other,vascular_tumor_cell_type,child_pugh_classification_grade,ca_19_9_level,ca_19_9_level_lower,ca_19_9_level_upper,fetoprotein_outcome_value,fetoprotein_outcome_lower_limit,fetoprotein_outcome_upper_limit,platelet_result_count,platelet_result_lower_limit,platelet_result_upper_limit,prothrombin_time_result_value,inter_norm_ratio_lower_limit,intern_norm_ratio_upper_limit,albumin_result_specified_value,albumin_result_lower_limit,albumin_result_upper_limit,bilirubin_upper_limit,bilirubin_lower_limit,total_bilirubin_upper_limit,creatinine_value_in_mg_dl,creatinine_lower_level,creatinine_upper_limit,fibrosis_ishak_score,cholangitis_tissue_evidence,new_tumor_event_liver_transplant,days_to_new_tumor_event_transplant,residual_disease_new_tumor_event,new_tumor_event_ablation_embo_tx,histological_type_list,history_myasthenia_gravis,section_myasthenia_gravis,person_occupation_description_text,occupation_primary_job,chemical_exposure_text,person_primary_industry_text,person_occupation_years_number,cancer_diagnosis_cancer_type_icd9_text_name,diagnosis_subtype,disease_extracapsular_extension_ind-3,bladder_carcinoma_extracapsular_extension_status,person_concomitant_prostate_carcinoma_occurrence_indicator,person_concomitant_prostate_carcinoma_pathologic_t_stage,history_non_muscle_invasive_blca,hist_of_non_mibc,non_mibc_tx,mibc_90day_post_resection_bcg,complete_response_observed,induction_course_complete,maint_therapy_course_complete,resp_maint_from_bcg_admin_month_dur,adjacent_hepatic_tissue_inflammation_extent_type,viral_hepatitis_serologies,viral_hepatitis_serology,ablations,adenocarcinoma_invasion,surgery_performed_type,histologic_grading_tier_category,alcoholic_exposure_category,history_of_diabetes,days_to_diabetes_onset,history_of_chronic_pancreatitis,days_to_pancreatitis_onset,relative_cancer_types,relative_cancer_type,type_of_progression_after_ht,adjuvant_rad_therapy_prior_admin,days_to_brachytherapy_begin_occurrence,days_to_brachytherapy_end_occurrence,brachytherapy_administered_status,radiation_supplemental,external_beam_radiation_therapy_administered_status,chemotherapy_regimen_types,days_to_chemotherapy_start,days_to_chemotherapy_end,presence_of_sarcomatoid_features,percent_tumor_sarcomatoid,days_from_date_of_initial_pathologic_diagnosis_to_date_of_birth,leukemia_specimen_cell_source_type,cumulative_agent_total_dose,prior_hematologic_disorder_diagnosis_indicator,hydroxyurea_agent_administered_day_count,hydroxyurea_administration_prior_registration_clinical_study_indicator,atra_exposure,steroid_therapy_administered,person_history_nonmedical_leukemia_causing_agent_type,person_history_leukemogenic_agent_other_exposure_text,lab_procedure_blast_cell_outcome_percentage_value,leukemia_french_american_british_morphology_code,immunophenotype_cytochemistry_testing_results,immunophenotype_cytochemistry_testing_result_values,immunophenotype_cytochemistry_testing_result,immunophenotype_cytochemistry_percent_positive,lab_procedure_bone_marrow_cellularity_outcome_percent_value,lab_procedure_leukocyte_result_unspecified_value,lab_procedure_hemoglobin_result_specified_value,lab_procedure_hematocrit_outcome_percent_value,lab_procedure_bone_marrow_blast_cell_outcome_percent_value,lab_procedure_bone_marrow_promyelocyte_result_percent_value,lab_procedure_bone_marrow_myelocyte_result_percent_value,lab_procedure_bone_marrow_metamyelocyte_result_value,lab_procedure_bone_marrow_band_cell_result_percent_value,lab_procedure_bone_marrow_neutrophil_result_percent_value,lab_procedure_bone_marrow_lab_eosinophil_result_percent_value,lab_procedure_bone_marrow_basophil_result_percent_value,lab_procedure_bone_marrow_lymphocyte_outcome_percent_value,lab_procedure_monocyte_result_percent_value,lab_procedure_bone_marrow_prolymphocyte_result_percent_value,lab_procedure_bone_marrow_promonocyte_count_result_percent_value,lab_procedure_abnormal_lymphocyte_result_percent_value,lab_procedure_bone_marrow_diff_not_reported_reason,cytogenetic_analysis_performed_ind,fluorescence_in_situ_hybrid_cytogenetics_metaphase_nucleus_result_count,acute_myeloid_leukemia_calgb_cytogenetics_risk_category,cytogenetic_abnormalities,cytogenetic_abnormality_other,fish_evaluation_performed_ind,fluorescence_in_situ_hybridization_abnormal_result_indicator,FISH_test_component_results,disease_detection_molecular_analysis_method_type,disease_detection_molecular_analysis_method_type_other_text,molecular_analysis_abnormal_result_indicator,molecular_analysis_abnormality_testing_results,molecular_analysis_abnormality_testing_result_values,molecular_analysis_abnormality_testing_result,molecular_analysis_abnormality_testing_percentage_value,FISH_test_component_result,FISH_test_component,FISH_test_component_percentage_value,fdg_or_ct_pet_performed_outcome,ablation,bcr_ablation_barcode,bcr_ablation_uuid,ablation_treatments,ablation_performed_indicator,embolization_treatments,embolization_performed_indicator,embolization_treatment,embolization_type,days_to_embolization_performed,embolization_therapy_drug_name,embolization_therapy_drug_name_other,embolizing_agent_utilized,embolizing_agent_utilized_other,pleurodesis_performed,pleurodesis_performed_90_days,history_asbestos_exposure,asbestos_exposure_type,asbestos_exposure_source,asbestos_exposure_age,asbestos_exposure_years,asbestos_exposure_age_last,primary_occupation,primary_occupation_other,family_history_cancer_type,family_history_cancer_type_other,serum_mesothelin_prior_tx,serum_mesothelin_lower_limit,serum_mesothelin_upper_limit,creatinine_prior_tx,creatinine_norm_range_lower,creatinine_norm_range_upper,suv_of_pleura_max,mesothelioma_detection_method,ablation_treatment,ablation_type,ablation_type_other,treatment_cycles_count,days_to_ablation_performed,lesions_count,additional_study,project_code,disease_code,diagnostic_mri_result_outcome
